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INTRODUCTION
The kidney is both a cause and victim of hypertension. 
High blood pressure is a key pathogenetic factor that 
contributes to deterioration of kidney function. Presence 
of kidney disease is a common and underappreciated 
pre-existing medical cause of resistant hypertension [1]. 
Therefore, treatment of hypertension has become the 
most important intervention in the management of all 
forms of chronic kidney disease (CKD). For this reason, 
the World Kidney Day that took place on March 12, 2009 
emphasized the role of hypertension in renal disease.
HOW DOES ONE RECOGNIZE THE 
PRESENCE OF CKD?
In contrast to a decade ago, most laboratories around the 
world today report estimated glomerular filtration rate 
(eGFR) instead of or in addition to serum creatinine. 
This now provides the physician with information about 
kidney function that is, in general, more informative. 
As a result, a greater percentage of patients with diabe-
tes or hypertension and their physicians have a better 
knowledge of their kidney function. Assessment of 
eGFR as an index of kidney function should be com-
plemented with the assessment of urine for protein or 
albu min (preferred).
Despite these laboratory updates, however, recent 
data demonstrate that a given patient’s knowledge that 
s/he has CKD is very low. In a recent analysis of almost 
half a million people in Taiwan who took part in a stan-
dard medical screening program, 12% had CKD [2]. It 
was noteworthy that < 4% of those with CKD were 
aware of their condition. People with CKD are several 
times more likely to die from cardiovascular (CV) 
causes than those with out CKD, thus, hypertension is a 
major risk factor in this context [3]. The combination 
of CKD and hypertension, therefore, is a major public 
health issue; because of the costly treatments necessary 
for end-stage renal dis ease (ESRD), end-stage CKD has 
also become a substantial burden to health budgets.
WHAT IS THE WORLDWIDE FREQUENCY 
OF CKD?
The frequency of CKD continues to increase worldwide 
as does the prevalence of ESRD [4,5]. The most com-
mon, but not only, causes of CKD are hypertension and 
diabetes. The presence of CKD is associated with a large 
increase in CV risk. Moreover, CV risk increases propor-
tionally as eGFR falls below 60 mL/min/1.73 m2. Lastly, 
death from CV causes is higher in patients with CKD 
than in those without, and much higher than is cancer 
in CKD. As a result, the identification and reduction of 
CKD has become a public health priority [6].
Between 1999 and 2006 in the most recent NHANES 
(national health and nutrition examination survey), rep-
resenting United States residents aged ≥ 20 years, 3.4 
million out of ∼26 million adult participants had CKD 
stages 1–4. Of these, 65.3% had CKD stage 3 or 4. Those 
with diabetes and hypertension had far greater preva-
lence of CKD (37% and 26%, respectively) compared 
to those with out these conditions (11% and 8%, respec-
tively) [7].
The most recent report of the United States Renal 
Data System estimates that nearly half a million patients 
in the United States were treated for ESRD in the year 
2004 [8], and by 2010 this figure is expected to increase 
by approximately 40%. Patients destined to progress to 
ESRD, i.e. the elderly, are a growing segment of the 
population. Additionally, males and African-Americans 
with pre-existing hypertension and CKD are also at 
much higher risk for ESRD [9]. This observation has 
also been confirmed throughout the developed world: 
Europe, Asia, Australia and regions of India and Africa 
[4,5].
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THE ROLE OF HYPERTENSION
Hypertension is a global problem, and the situation is 
pro jected to get worse. It is the major risk factor for 
development and progression in nondiabetic and dia-
betic CKD.
The world population is getting older, and aging is 
the most common risk factor for the development of 
hypertension and diabetes as well as CKD. Nearly one 
billion people worldwide have high blood pressure 
(defined as > 140/90 mmHg), and that number is ex-
pected to increase to 1.56 billion people by 2025 [10]. 
The prevalence of hypertension is predicted to increase 
by 24% in developed countries and by 80% in develop-
ing regions such as Africa and Latin America. One report 
noted that 333 million adults in economically developed 
regions such as North America and Europe had high 
blood pressure in 2000, and an additional 639 million 
people in developing countries have this condition.
In 1999–2006, the prevalence of hypertension in 
U.S. adults was 43.4% when defined as > 140/90 mmHg, 
and similar figures have been reported from many 
Western countries [9]. The rates of hypertension were 
highest in participants who were aged > 60 years (i.e. 
68–80% versus 25% in those 20–39 years of age), and 
in non-Hispanic blacks (53%) versus Caucasians (43%) 
versus Mexican-Americans (34%). Furthermore, hyper-
tension was more common in individuals with a higher 
body mass index (BMI) (60% for BMI ≥ 35 vs. 32% for 
BMI = 23). Slightly more than half of adults with hy-
pertension were aware of their disease in 1999–2004; 
fewer than half were treated for their hypertension with 
medications; and fewer than two-thirds were controlled 
to < 140/90 mmHg with medication [9]. This trend in 
poor blood pressure control is observed worldwide.
The hypertension control rate is substantially less in 
patients with CKD, particularly in those with diabetes 
and CKD [1,9]. This is illustrated by the U.S. National 
Kidney Foundation’s Kidney Early Evaluation Program 
(KEEP), a health-screening program for individuals at 
high risk for kidney disease [9]. The prevalence (86.2%), 
awareness (80.2%), and treatment (70.0%) of hyper-
tension in the screened cohort were high, but blood 
pressure control rates were low (13.2%). The proportion 
of hypertensive patients increased with advancing stages 
of CKD.
WHICH BLOOD PRESSURE COMPONENT IS 
MOST RELEVANT FOR RENAL AND CV RISK, 
SYSTOLIC OR DIASTOLIC?
There is now consensus, based on the totality of the 
data, that systolic rather than diastolic blood pressure 
poses the greater risk for CV events and kidney disease 
progression. Against this background, it is relevant that 
in the KEEP study, elevated systolic blood pressure 
accounted for the majority of patients with inadequate 
control. Male gender, non-Hispanic black race, and 
BMI ≥ 30 kg/m2 were inversely related to blood pressure 
control.
What is the blood pressure target for CKD patients? 
According to the different guidelines published by the 
major kidney societies, systolic blood pressure should 
be lowered to < 130 or 125 mmHg if > 1 g/day of pro-
teinuria is present. One has to be aware, however, that 
as a predictor of adverse CKD or CV events, office blood 
pres sure may be inferior compared to ambulatory blood 
pressure measurement [11]. This issue is particularly 
rel evant in CKD because of the tendency for night-time 
blood pressure to be elevated (little or no nocturnal 
dip in blood pressure) and the fact that central (aortic) 
blood pressure tends to be higher than peripheral (bra-
chial) blood pressure [11,12]. In patients with diabetes, 
guidelines all recommend that lower blood pressure 
targets may provide further benefit, but prospective tri-
als have thus far failed to confirm this epidemiologic 
observation.
THE ROLE OF DIABETIC NEPHROPATHY
As indicated above, diabetes and hypertension are the 
most common causes of CKD. There are currently over 
240 million people with diabetes worldwide. This figure 
is projected to rise to 380 million by 2025, largely due 
to population growth, aging, urbanization, unhealthy 
eating habits, increased body fat and a sedentary lifestyle. 
By 2025, the number of people with diabetes is expected 
to more than double in South-East Asia, the Eastern 
Mediterranean and Middle East, and Africa. It is pro-
jected to rise by nearly 20% in Europe, 50% in North 
America, 85% in South and Central America and 75% 
in the Western Pacific region. The top five countries 
with the highest prevalence of diabetes in order include 
India, China, the United States, Russia and Japan. 
Worldwide, more than 50% of people with diabetes are 
unaware of their condition and are not treated.
The same behaviors that increase obesity are shared 
by those predisposed to diabetes, i.e. family history, 
pre sence of hypertension, aging, excess body weight, 
lack of exercise, and unhealthy dietary habits. It is im-
portant to identify these risks early to reduce the devel-
opment of diabetes and CKD, since CKD greatly 
amplifies the risk of CV events in the diabetic patient.
THE REMAINING CHALLENGE
Under-diagnosis and under-treatment of CKD is a world-
wide problem: not only is CKD awareness low world-
wide, but the relative lack of CKD risk factor awareness 
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 Hypertension and kidney disease
by physicians (i.e. hypertension and diabetes) is even 
more disturbing. Moreover, even awareness of these risk 
factors does not ensure adequate treatment; this could 
relate either to the behavior of the patient, the health 
care provider or both. Thus, the problem of CKD remains 
a challenge as exemplified by recent data showing that 
between 1999 and 2006, less than 5% of people with 
eGFR < 60 mL/min/1.73 m2 and proteinuria were aware 
that they had CKD; of those with CKD stage 3, aware-
ness was only 7.5%; for stage 4, awareness was < 50%. 
Awareness rates among those with CKD stages 3 or 4 
were higher if comorbid diagnoses of diabetes and hy-
pertension were present, but even then, they were quite 
low (20% and 12%, respectively).
One barrier to overcome in order to ensure greater 
awareness is a more focused education of physicians, 
since they are the purveyors of the patients’ medical 
condition. In one survey, more than one third of primary 
care physicians in the U.S. were not aware that family 
history was a risk factor for CKD, while almost one 
quarter did not consider African-American ethnicity to 
be a CKD risk factor. In contrast, nearly all identified 
diabetes (95%) and hypertension (97%) as risk factors 
for CKD. But even more problematic was the fact that 
while diabetes and hypertension were acknowledged as 
CKD risk factors, the achieved control rates (defined as 
reaching guideline goals) sadly remain well below 50% 
among those treated.
WHAT CAN BE DONE ABOUT THIS PROBLEM?
There have been many consensus panels over the past 
decade to approach ways to achieve better blood pres-
sure control and educate physicians with regard to the 
stages of CKD [13,14]. The road to improve outcomes 
is to focus on public awareness and screening programs, 
as well as on programs to educate both patients and 
physicians. Data from the KEEP screening program in 
the U.S. have also indicated that blood pressure values 
are most likely to be at goal once a patient is aware that 
they have kidney disease [15]. Data from Bolivia high-
lights the observation that once kidney disease is diag-
nosed, more appropriate interventions to reduce CKD 
risk factors such as hypertension are instituted [13].
Programs to address these issues have started around 
the world, including KEEP type programs. A major focus 
of World Kidney Day this year was the issue of hyper-
tension in CKD (http://www.worldkidneyday.org).
Because of the aging world population and conse-
quent increasing prevalence of hypertension and diabe-
tes, CKD rates will continue to increase. This has and 
will continue to place an undue economic burden on 
societies given the costs of an ESRD program. In 2005, 
the U.S. spent $32 billion dollars on such programs. 
These facts mandate that measures be put forth to ensure 
timely detection and prevention of CKD progression. 
The key to ensure successful prevention of CKD is 
screening for hypertension, improved testing and diag-
nosis of predisposing comorbidities such as diabetes, 
and aggressive treatment to guideline goals.
The International Society of Nephrology and the 
International Federation of Kidney Foundations have 
an ambitious long-term goal that worldwide, every in-
dividual, particularly the patient with diabetes, knows 
his/her blood pressure values. Additionally, they should 
be aware that prompt treatment is necessary once blood 
pressure values are no longer in the normal range. Finally, 
our societies strongly encourage public health authori-
ties to support efforts to raise public awareness of CKD 
and promote moves to reduce the risk of developing hy-
pertension. Such governmental public health initiatives 
are exemplified by countries like the United Kingdom, 
Finland and Japan reducing salt in the diet, and mandat-
ing labels to show the sodium content as in the U.S. 
These initiatives have proven to be highly successful 
based on reductions in CV mortality and morbidity.
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